Michael Tetzlaff, MD, PhD
SESSIONS
F024 A Primer and Practical Approach to Cancer Checkpoint Inhibitors for the Dermatologist
Mar 28, 2026
•
9:00 AM - 11:00 AM
•
Bluebird 1B
S060 Melanoma in 2026
Mar 30, 2026
•
1:00 PM - 4:00 PM
•
Mile High 1D
U101 Dysplastic Nevi for Dummies
Mar 30, 2026
•
4:30 PM - 5:30 PM
•
Bluebird 3A
DISCLOSURES
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);